Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 May 31;2013(5):CD010538.
doi: 10.1002/14651858.CD010538.

Topical herbal therapies for treating osteoarthritis

Affiliations
Review

Topical herbal therapies for treating osteoarthritis

Melainie Cameron et al. Cochrane Database Syst Rev. .

Abstract

Background: Before extraction and synthetic chemistry were invented, musculoskeletal complaints were treated with preparations from medicinal plants. They were either administered orally or topically. In contrast to the oral medicinal plant products, topicals act in part as counterirritants or are toxic when given orally.

Objectives: To update the previous Cochrane review of herbal therapy for osteoarthritis from 2000 by evaluating the evidence on effectiveness for topical medicinal plant products.

Search methods: Databases for mainstream and complementary medicine were searched using terms to include all forms of arthritis combined with medicinal plant products. We searched electronic databases (Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, AMED, CINAHL, ISI Web of Science, World Health Organization Clinical Trials Registry Platform) to February 2013, unrestricted by language. We also searched the reference lists from retrieved trials.

Selection criteria: Randomised controlled trials of herbal interventions used topically, compared with inert (placebo) or active controls, in people with osteoarthritis were included.

Data collection and analysis: Two review authors independently selected trials for inclusion, assessed the risk of bias of included studies and extracted data.

Main results: Seven studies (six different medicinal plant interventions; 785 participants) were included. Single studies (five studies) and non-comparable studies (two studies) precluded pooling of results.Moderate evidence from a single study of 174 people with hand osteoarthritis indicated that treatment with Arnica extract gel probably results in similar benefits as treatment with ibuprofen (non-steroidal anti-inflammatory drug) with a similar number of adverse events. Mean pain in the ibuprofen group was 44.2 points on a 100 point scale; treatment with Arnica gel reduced the pain by 4 points after three weeks: mean difference (MD) -3.8 points (95% confidence intervals (CI) -10.1 to 2.5), absolute reduction 4% (10% reduction to 3% increase). Hand function was 7.5 points on a 30 point scale in the ibuprofen-treated group; treatment with Arnica gel reduced function by 0.4 points (MD -0.4, 95% CI -1.75 to 0.95), absolute improvement 1% (6% improvement to 3% decline)). Total adverse events were higher in the Arnica gel group (13% compared to 8% in the ibuprofen group): relative risk (RR) 1.65 (95% CI 0.72 to 3.76).Moderate quality evidence from a single trial of 99 people with knee osteoarthritis indicated that compared with placebo, Capsicum extract gel probably does not improve pain or knee function, and is commonly associated with treatment-related adverse events including skin irritation and a burning sensation. At four weeks follow-up, mean pain in the placebo group was 46 points on a 100 point scale; treatment with Capsicum extract reduced pain by 1 point (MD -1, 95% CI -6.8 to 4.8), absolute reduction of 1% (7% reduction to 5% increase). Mean knee function in the placebo group was 34.8 points on a 96 point scale at four weeks; treatment with Capsicum extract improved function by a mean of 2.6 points (MD -2.6, 95% CI -9.5 to 4.2), an absolute improvement of 3% (10% improvement to 4% decline). Adverse event rates were greater in the Capsicum extract group (80% compared with 20% in the placebo group, rate ratio 4.12, 95% CI 3.30 to 5.17). The number needed to treat to result in adverse events was 2 (95% CI 1 to 2).Moderate evidence from a single trial of 220 people with knee osteoarthritis suggested that comfrey extract gel probably improves pain without increasing adverse events. At three weeks, the mean pain in the placebo group was 83.5 points on a 100 point scale. Treatment with comfrey reduced pain by a mean of 41.5 points (MD -41.5, 95% CI -48 to -34), an absolute reduction of 42% (34% to 48% reduction). Function was not reported. Adverse events were similar: 6% (7/110) reported adverse events in the comfrey group compared with 14% (15/110) in the placebo group (RR 0.47, 95% CI 0.20 to 1.10).Although evidence from a single trial indicated that adhesive patches containing Chinese herbal mixtures FNZG and SJG may improve pain and function, the clinical applicability of these findings are uncertain because participants were only treated and followed up for seven days. We are also uncertain if other topical herbal products (Marhame-Mafasel compress, stinging nettle leaf) improve osteoarthritis symptoms due to the very low quality evidence from single trials.No serious side effects were reported.

Authors' conclusions: Although the mechanism of action of the topical medicinal plant products provides a rationale basis for their use in the treatment of osteoarthritis, the quality and quantity of current research studies of effectiveness are insufficient. Arnica gel probably improves symptoms as effectively as a gel containing non-steroidal anti-inflammatory drug, but with no better (and possibly worse) adverse event profile. Comfrey extract gel probably improves pain, and Capsicum extract gel probably will not improve pain or function at the doses examined in this review. Further high quality, fully powered studies are required to confirm the trends of effectiveness identifed in studies so far.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Arnica versus ibuprofen, Outcome 1 Pain VAS 0‐100.
1.2
1.2. Analysis
Comparison 1 Arnica versus ibuprofen, Outcome 2 28 painful joint count change from baseline.
1.3
1.3. Analysis
Comparison 1 Arnica versus ibuprofen, Outcome 3 Intensity of morning stiffness (1 to 5) change from baseline.
1.4
1.4. Analysis
Comparison 1 Arnica versus ibuprofen, Outcome 4 Duration of morning stiffness (1 to 5) change from baseline.
1.5
1.5. Analysis
Comparison 1 Arnica versus ibuprofen, Outcome 5 Hand algofunctional index (0 to 30).
1.6
1.6. Analysis
Comparison 1 Arnica versus ibuprofen, Outcome 6 Cumulative dose of analgesics (acetominophen mg) over 3 weeks.
1.7
1.7. Analysis
Comparison 1 Arnica versus ibuprofen, Outcome 7 Participants (n) reported adverse events.
2.1
2.1. Analysis
Comparison 2 Capsaicin 0.0125% versus placebo, Outcome 1 Pain VAS 0‐100.
2.2
2.2. Analysis
Comparison 2 Capsaicin 0.0125% versus placebo, Outcome 2 WOMAC 0‐4 (Overall).
2.3
2.3. Analysis
Comparison 2 Capsaicin 0.0125% versus placebo, Outcome 3 Adverse event episodes (n) reported.
3.1
3.1. Analysis
Comparison 3 Comfrey versus placebo, Outcome 1 Pain VAS 0‐100.
3.2
3.2. Analysis
Comparison 3 Comfrey versus placebo, Outcome 2 Pain VAS 0‐100 change from baseline.
3.3
3.3. Analysis
Comparison 3 Comfrey versus placebo, Outcome 3 Pain VAS 0‐100 (at rest) change from baseline.
3.4
3.4. Analysis
Comparison 3 Comfrey versus placebo, Outcome 4 Pain VAS 0‐100 (movement) change from baseline.
3.5
3.5. Analysis
Comparison 3 Comfrey versus placebo, Outcome 5 WOMAC‐VAS (Pain) change from baseline.
3.6
3.6. Analysis
Comparison 3 Comfrey versus placebo, Outcome 6 WOMAC‐VAS (Stiffness) change from baseline.
3.7
3.7. Analysis
Comparison 3 Comfrey versus placebo, Outcome 7 WOMAC‐VAS (Function) change from baseline.
3.8
3.8. Analysis
Comparison 3 Comfrey versus placebo, Outcome 8 WOMAC‐VAS (Overall) change from baseline.
3.9
3.9. Analysis
Comparison 3 Comfrey versus placebo, Outcome 9 Change in SF‐36 physical component summary score.
3.10
3.10. Analysis
Comparison 3 Comfrey versus placebo, Outcome 10 Change in SF‐36 mental component summary score.
3.11
3.11. Analysis
Comparison 3 Comfrey versus placebo, Outcome 11 Participants (n) reported adverse events.
4.1
4.1. Analysis
Comparison 4 Marhame‐Mafasel versus placebo, Outcome 1 WOMAC‐VAS (Pain) change from baseline.
4.2
4.2. Analysis
Comparison 4 Marhame‐Mafasel versus placebo, Outcome 2 WOMAC‐VAS (Stiffness) change from baseline.
4.3
4.3. Analysis
Comparison 4 Marhame‐Mafasel versus placebo, Outcome 3 WOMAC‐VAS (Function) change from baseline.
4.4
4.4. Analysis
Comparison 4 Marhame‐Mafasel versus placebo, Outcome 4 WOMAC‐VAS (Overall) change from baseline.
4.5
4.5. Analysis
Comparison 4 Marhame‐Mafasel versus placebo, Outcome 5 Participants (n) reporting adverse events.
5.1
5.1. Analysis
Comparison 5 Stinging nettle versus placebo, Outcome 1 WOMAC 0‐4 (Pain) at 1 week.
5.2
5.2. Analysis
Comparison 5 Stinging nettle versus placebo, Outcome 2 WOMAC 0‐4 (Stiffness) at 4 weeks.
5.3
5.3. Analysis
Comparison 5 Stinging nettle versus placebo, Outcome 3 WOMAC 0‐4 (Function) at 4 weeks.
5.4
5.4. Analysis
Comparison 5 Stinging nettle versus placebo, Outcome 4 Participants (n) reported adverse events.
6.1
6.1. Analysis
Comparison 6 FNZG versus placebo, Outcome 1 Pain on walking VAS 0‐100.
6.2
6.2. Analysis
Comparison 6 FNZG versus placebo, Outcome 2 WOMAC 0‐4 (Pain).
6.3
6.3. Analysis
Comparison 6 FNZG versus placebo, Outcome 3 WOMAC 0‐4 (Stiffness).
6.4
6.4. Analysis
Comparison 6 FNZG versus placebo, Outcome 4 WOMAC 0‐4 (Function).
6.5
6.5. Analysis
Comparison 6 FNZG versus placebo, Outcome 5 WOMAC 0‐4 (Overall).
6.6
6.6. Analysis
Comparison 6 FNZG versus placebo, Outcome 6 Participants (n) reported adverse events..
7.1
7.1. Analysis
Comparison 7 SJG versus placebo, Outcome 1 Pain on walking VAS 0‐100.
7.2
7.2. Analysis
Comparison 7 SJG versus placebo, Outcome 2 WOMAC 0‐4 (Pain).
7.3
7.3. Analysis
Comparison 7 SJG versus placebo, Outcome 3 WOMAC 0‐4 (Stiffness).
7.4
7.4. Analysis
Comparison 7 SJG versus placebo, Outcome 4 WOMAC 0‐4 (Function).
7.5
7.5. Analysis
Comparison 7 SJG versus placebo, Outcome 5 WOMAC 0‐4 (Overall).
7.6
7.6. Analysis
Comparison 7 SJG versus placebo, Outcome 6 Participants (n) reported adverse events.
8.1
8.1. Analysis
Comparison 8 FNZG versus SJG, Outcome 1 Pain on walking VAS 0‐100.
8.2
8.2. Analysis
Comparison 8 FNZG versus SJG, Outcome 2 WOMAC 0‐4 (Pain).
8.3
8.3. Analysis
Comparison 8 FNZG versus SJG, Outcome 3 WOMAC 0‐4 (Stiffness).
8.4
8.4. Analysis
Comparison 8 FNZG versus SJG, Outcome 4 WOMAC 0‐4 (Function).
8.5
8.5. Analysis
Comparison 8 FNZG versus SJG, Outcome 5 WOMAC 0‐4 (Overall).
8.6
8.6. Analysis
Comparison 8 FNZG versus SJG, Outcome 6 Participants (n) reported adverse events.

Similar articles

  • Oral herbal therapies for treating osteoarthritis.
    Cameron M, Chrubasik S. Cameron M, et al. Cochrane Database Syst Rev. 2014 May 22;2014(5):CD002947. doi: 10.1002/14651858.CD002947.pub2. Cochrane Database Syst Rev. 2014. PMID: 24848732 Free PMC article. Review.
  • Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears).
    O'Connor D, Johnston RV, Brignardello-Petersen R, Poolman RW, Cyril S, Vandvik PO, Buchbinder R. O'Connor D, et al. Cochrane Database Syst Rev. 2022 Mar 3;3(3):CD014328. doi: 10.1002/14651858.CD014328. Cochrane Database Syst Rev. 2022. PMID: 35238404 Free PMC article. Review.
  • Herbal medicine for low-back pain.
    Oltean H, Robbins C, van Tulder MW, Berman BM, Bombardier C, Gagnier JJ. Oltean H, et al. Cochrane Database Syst Rev. 2014 Dec 23;2014(12):CD004504. doi: 10.1002/14651858.CD004504.pub4. Cochrane Database Syst Rev. 2014. PMID: 25536022 Free PMC article. Review.
  • Tramadol for osteoarthritis.
    Toupin April K, Bisaillon J, Welch V, Maxwell LJ, Jüni P, Rutjes AW, Husni ME, Vincent J, El Hindi T, Wells GA, Tugwell P. Toupin April K, et al. Cochrane Database Syst Rev. 2019 May 27;5(5):CD005522. doi: 10.1002/14651858.CD005522.pub3. Cochrane Database Syst Rev. 2019. PMID: 31132298 Free PMC article.
  • Chondroitin for osteoarthritis.
    Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Singh JA, et al. Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD005614. doi: 10.1002/14651858.CD005614.pub2. Cochrane Database Syst Rev. 2015. PMID: 25629804 Free PMC article. Review.

Cited by

References

References to studies included in this review

Grube 2007 {published data only}
    1. Grube B, Grunwuld J, Krug L, Staiger C. Efficacy of a comfrey root (Symphyti offic. radix) extract ointment in the treatment of patients with painful osteoarthritis of the knee: Results of a double‐blind, randomised, bicenter, placebo‐controlled trial. Phytomedicine 2007;14(1):2‐10. - PubMed
Kosuwon 2010 {published data only}
    1. Kosuwon W, Sirichatiwapee W, Wisanuyotin T, Jeeravipoolvarn P, Laupattarakasem W. Efficacy of symptomatic control of knee osteoarthritis with 0.0125% of capsaicin versus placebo. Journal of the Medical Association of Thailand 2010;93:1188‐95. - PubMed
Randall 2000 {published data only}
    1. Randall C, Randall H, Dobbs F, Hutton C, Sanders H. Randomized controlled trial of nettle sting for treatment of base‐of‐thumb pain. Journal of the Royal Society of Medicine 2000;93:305‐9. - PMC - PubMed
Randall 2008 {published data only}
    1. Randall C, Dickens A, White A, Sanders H, Fox M, Campbell J. Nettle sting for chronic knee pain: A randomised controlled pilot study. Complementary Therapies in Medicine 2008;16:66‐72. [DOI: 10.1016/j.ctim.2007.01.012] - DOI - PubMed
Soltanian 2010 {published data only}
    1. Soltanian AR, Mehdibarzi D, Faghihzadeh S, Naseri M, Gerami A. Mixture of Arnebia euchroma and Matricaria chamomilla (Marhame‐Mafasel) for pain relief of osteoarthritis of the knee ‐ a two‐treatment, two‐period crossover trial. Archives of Medical Science 2010;6(6):950‐5. [DOI: 10.5114/aoms.2010.19307] - DOI - PMC - PubMed
Wang 2012 {published data only}
    1. Wang X, Cao Y, Pang J, Du J, Guo C, Liu T, et al. Traditional chinese herbal patch for short‐term management of knee osteoarthritis: a randomized, double‐blind, placebo‐controlled trial. Evidence‐based Complementary and Alternative Medicine 2012;2012:1‐9. [DOI: 10.1155/2012/171706] - DOI - PMC - PubMed
Widrig 2007 {published data only}
    1. Widrig R, Suter A, Saller R, Melzer J. Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double‐blind study. Rheumatology International 2007;27:585‐91. [DOI: 10.1007/s00296-007-0304-y] - DOI - PubMed

References to studies excluded from this review

Altman 1994 {published data only}
    1. Altman RD, Aven A, Holmburg E, Pfeifer LM. Capsaicin cream 0.025% as monotherapy for osteoarthritis: A double‐blind study. Seminars in Arthritis and Rheumatism 1994;23 Suppl 3:25‐32.
Deal 1991 {published data only}
    1. Deal CL, Schnitzer TJ, Lipstein E, Seibold JR, Stevens RM, Levy MD, et al. Treatment of arthritis with topical capsaicin: A double‐blind trial. Clinical Therapeutics 1991;13(3):383‐95. - PubMed
Gemmell 2003 {published data only}
    1. Gemmell HA, Jacobson BH, Hayes BM. Effect of a topical herbal cream on osteoarthritis of the hand and knee: A pilot study. Journal of Manipulative and Physiological Therapeutics 2003;26:e15. [DOI: 10.1016/S0161-4754(03)00009-5] - DOI - PubMed
Kielczynski 1997 {published data only}
    1. Kielczynski W. Osteoarthritis ‐ clinical outcomes after uniform, long‐term herbal treatment. The European Journal of Herbal Medicine 1997;3(2):29‐35.
Linsheng 1997 {published data only}
    1. Linsheng W. Treatment of bony arthritis with herbal medicine and by massotherapy ‐ analysis of 121 cases. Journal of Traditional Chinese Medicine 1997;17(1):32‐6. - PubMed
Long 2001 {published data only}
    1. Long L, Soeken K, Ernst E. Herbal medicines for the treatment of osteoarthritis: A systematic review. Rheumatology 2001;40:779‐93. - PubMed
McCarthy 1992 {published data only}
    1. McCarthy GM, McCarthy DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. The Journal of Rheumatology 1992;19(4):604‐7. - PubMed
McCleane 2000 {published data only}
    1. McCleane G. The analgesic efficacy of topical capsaicin is enhanced by glyceryl trinitrate in painful osteoarthritis: A randomized, double blind, placebo controlled study. European Journal of Pain 2000;4:355‐60. - PubMed
McKay 2003 {published data only}
    1. McKay L, Gemmell H, Jacobson B, Hayes B. Effect of a topical herabl cream on the pain and stiffness of osteoarthritis. Clinical Rheumatology 2003;9(3):164‐9. [DOI: 10.1097/01.RHU.0000073450.85179.55] - DOI - PubMed
Rayburn 2009 {published data only}
    1. Rayburn K, Fleischbein E, Song J, Allen B, Kundert M, Leiter C, et al. Stinging nettle cream for osteoarthritis. Alternative Therapies 2009;15:60‐1. - PubMed
Sagar 1988 {published data only}
    1. Sagar VMV. A clinical study of Amavata with special reference to some indigenous drugs. Rheumatism 1988‐89;24(3):3‐7.
Saley 1987 {published data only}
    1. Saley SR, Tilak MN, Deshmukh SS. Amavata ‐ a clinical study of 41 cases. Rheumatism 1987;22(2):46‐50.
Schnitzer 1994 {published data only}
    1. Schnitzer T, Morton C, Coker S. Topical capsaicin therapy for osteoarthritis pain: Achieving a maintenance regimen. Seminars in Arthritis and Rheumatism 1994;23 Suppl 3:34‐40.
Smith 2011 {published data only}
    1. Smith DB, Jacobson BH. Effect of a blend of comfrey root extract (Symphytum officinale L.) and tannic acid creams in the treatment of osteoarthritis of the knee: randomized, placebo‐controlled, double‐blind, multiclinical trials. Journal of Chiropractic Medicine 2011;10:147‐56. [DOI: 10.1016/j.jcm.2011.01.003] - DOI - PMC - PubMed
Wadnap 2006 {published data only}
    1. Wadnap N, Johnson J, Bhatt N, Chitre D. Efficacy and safety of RA11: A herbal cream. Indian Journal of Traditional Knowledge 2006;5:384‐7.
Yuelong 2011 {published data only}
    1. Yuelong C, Hongsheng Z, Jian P, Feiyue L, Shaojian X, Jinghua G, et al. Individually integrated traditional Chinese medicine approach in the management of knee osteoarthritis: study protocol for a randomized controlled trial. Trials 2011;12:160. [DOI: 10.1186/1745-6215-12-160] - DOI - PMC - PubMed

References to studies awaiting assessment

Zahmatkash 2011 {published data only}
    1. Zahmatkash M, Vafaeenasab MR. Comparing analgesic effects of a topical herbal mixed medicine with salicylate in patients with knee osteoarthritis. Pakistan Journal of Biological Science 2011;14(13):715‐9. - PubMed
Zhong 2006 {published data only}
    1. Zhong Q‐S, Ye G‐H, Wang H‐Z, Lin S‐H. Treatment of knee osteoarthritis by invigorating the kidney, dispelling the cold and activating the collaterals: A randomized controlled study. Chinese Journal of Clinical Rehabilitation 2006;10:177‐9.

References to ongoing studies

Youxin 2012 {unpublished data only}
    1. Youxin S. Rehabilitation protocol of the Traditional Chinese Medicine on patients with dyskinesia of the knee osteoarthritis: A randomized controlled trial study in community. Chinese Clinical Trial Registry 2012. [ChiCTR‐TRC‐12002538]

Additional references

Altman 1986
    1. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. The American College of Rheumatology crtieria for the classification and reporting of osteoarthritis of the knee. Arthritis and Rheumatism 1986;29:1039‐49. - PubMed
Altman 1990
    1. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis and Rheumatism 1990;33:1601‐1610. - PubMed
Altman 1991
    1. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis and Rheumatism 1991;34:505‐514. - PubMed
Anonymous 1998
    1. Anonymous. Urtica [Urtica]. In: Blaschek W, Hänsel R, Keller K, Reichling J, Rimpler H, Schneider G editor(s). Hagers Handbuch der Pharmazeutischen Praxis, Folgeband 3. Berlin, Heidelburg, New York: Springer Press, 1998:710‐732.
Anonymous 2007
    1. Anonymous. Final report on the safety assessment of capsicum annuum extract, capsicum annuumfruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin. International Journal of Toxicology 2007;Suppl 1:3‐106. - PubMed
Begg 1996
    1. Begg C, Cho M, Eastwood S, Horeton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT Statement. JAMA 1996;276(8):637‐9. - PubMed
Blumenthal 1998
    1. Blumenthal M. The complete German Commission E Monographs. Austin, TX: Americal Botanical Council, 1998.
Buck & Burks 1986
    1. Buck SH, Burks TF. The neuropharmacology of capsaicin: Review of some recent observations. Pharmacology Review 1986;38:179‐226. - PubMed
Chrubasik 2003
    1. Chrubasik S, Roufogalis B. Bioequivalence of herbal medicines. New Zealand Journal of Pharmacy 2003;53:39‐44.
Dedov 2000
    1. Dedov VN, Roufogalis BD. Mitochondrial calcium accumulation following activation of vanilloid (VR1) receptors by capsaicin in dorsal root ganglion neurons. Neuroscience 2000;95:183‐8. - PubMed
Dedov 2001
    1. Dedov VN, Mandadi S, Armati PJ, Verkhratsky A. Capsaicin‐induced depolarisation of mitochondria in dorsal root ganglion neurons is enhanced by vanilloid receptors. Neuroscience 2001;103:219‐26. - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Ekenäs 2008
    1. Ekenäs C, Zebrowska A, Schuler B, Vrede T, Andreasen K, Backlund A, et al. Screening for anti‐inflammatory activity of 12 Arnica (Asteraceae) species assessed by inhibition of NF‐kappaB and release of human neutrophil elastase. Planta Medica 2008;74:1789‐94. - PubMed
Englberger 1988
    1. Englberger W, Hadding U, Etschenberg E, Graf E, Leyck S, Winkelmann J, Parnham MJ. Rosmarinic acid: a new inhibitor of complement C3‐convertase with anti‐inflammatory activity. International Journal of Immunopharmacology 1988;10:729‐37. - PubMed
ESCOP 2003
    1. European Scientific Cooperative on Phytotherapy (Eds). ESCOP Monographs. New York: Thieme‐Verlag Stuttgart, 2003.
ESCOP 2009
    1. European Scientific Cooperative on Phytotherapy (Eds). ESCOP Monographs. Supplement. Stuttgart, New York: Thieme Press, 2009.
Flynn 1986
    1. Flynn DL, Rafferty MF, Boctor AM. Inhibition of human neutrophil 5‐lipoxygenase activity by gingerdione, shogaol, capsaicin and related pungent compounds. Prostoglandins, Leukotrienes, and Medicine 1986;24:195‐8. - PubMed
Galano 2012
    1. Galano A, Martínez A. Capsaicin, a tasty free radical scavenger: mechanism of action and kinetics. Journal of Physical Chemistry B 2012;116:1200‐8. - PubMed
Galeotti 2001
    1. Galeotti N, Ghelardini C, Mannelli L, Mazzanti G, Baghiroli L, Bartolini A. Local anaesthetic activity of (+)‐ and (‐)‐menthol. Planta Medica 2001;67:174‐6. - PubMed
Galeotti 2002
    1. Galeotti N, Cesare Mannelli L, Mazzanti G, Bartolini A, Ghelardini C. Menthol: a natural analgesic compound. Neuroscience Letters 2002;322:145‐8. - PubMed
Gaudioso 2012
    1. Gaudioso C, Hao J, Martin‐Eauclaire MF, Gabriac M, Delmas P. Menthol pain relief through cumulative inactivation of voltage‐gated sodium channels. Pain 2012;153:473‐84. - PubMed
Green 1992
    1. Green BG. The sensory effects of l‐menthol on human skin. Somatosensory & Motor Research 1992;9:235‐44. - PubMed
Hayes 2000
    1. Hayes P, Meadows HJ, Gunthorpe MJ, Harries MH, Duckworth DM, Cairns W, et al. Cloning and functional expression of a human orthologue of rat vanilloid receptor‐1. Pain 2000;88:205‐15. - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). The Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org., 2011.
Huang 2008
    1. Huang W, Wang H, Galligan JJ, Wang DH. Transient receptor potential vanilloid subtype 1 channel mediated neuropeptide secretion and depressor effects: role of endoplasmic reticulum associated Ca2+ release receptors in rat dorsal root ganglion neurons. Journal of Hypertension 2008;26:1966‐75. - PMC - PubMed
ICH 2004
    1. ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Synopsis of ICH guidelines and topics. Geneva, Switzerland: Author, 2004.
Johnson 2009
    1. Johnson CD, Melanaphy D, Purse A, Stokesberry SA, Dickson P, Zholos AV. Transient receptor potential melastatin 8 channel involvement in the regulation of vascular tone. American Journal of Physiology. Heart and Circulatory Physiology 2009;296:H1868‐77. - PMC - PubMed
Juergens 1998
    1. Juergens UR, Stöber M, Vetter H. The anti‐inflammatory activity of L‐menthol compared to mint oil in human monocytes in vitro: a novel perspective for its therapeutic use in inflammatory diseases. European Journal of Medical Research 1998;3:539‐45. - PubMed
Jäger 2009
    1. Jäger C, Hrenn A, Zwingmann J, Suter A, Merfort I. Phytomedicines prepared from Arnica flowers inhibit the transcription factors AP‐1 and NF‐kappaB and modulate the activity of MMP1 and MMP13 in human and bovine chondrocytes. Planta Medica 2009;75:1319‐25 . - PubMed
Ka 2005
    1. Ka MH, Choi EH, Chun HS, Lee KG. Antioxidative activity of volatile extracts isolated from Angelica tenuissimae roots, peppermint leaves, pine needles, and sweet flag leaves. Journal of Agricultural and Food Chemistry 2005;53:4124‐9. - PubMed
Karashima 2007
    1. Karashima Y, Damann N, Prenen J, Talavera K, Segal A, Voets T, Nilius B. Bimodal action of menthol on the transient receptor potential channel TRPA1. Journal of Neuroscience 2007;27:9874‐84. - PMC - PubMed
Kim 2003
    1. Kim CS, Kawada T, Kim BS, Han IS, Choe SY, Kurata T, Yu R. Capsaicin exhibits anti‐inflammatory property by inhibiting IkB‐a degradation in LPS‐stimulated peritoneal macrophages. Cell Signal 2003;15:299‐306. - PubMed
Klaas 2002
    1. Klaas CA, Wagner G, Laufer S, Sosa S, Della Loggia R, Bomme U, et al. Studies on the anti‐inflammatory activity of phytopharmaceuticals prepared from arnica flowers. Planta Medica 2002;68:385‐91. - PubMed
Lawrence 2008
    1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis and Rheumatism 2008;58:26‐35. - PMC - PubMed
Lee 2006
    1. Lee J, Jung E, Kim Y, Lee J, Park J, Hong S, et al. Rosmarinic acid as a downstream inhibitor of IKK‐beta in TNF‐alpha‐induced upregulation of CCL11 and CCR3. British Journal of Pharmacology 2006;148:366‐75. - PMC - PubMed
Li 2011
    1. Li N, Xia Q, Ruan J, Fu PP, Lin G. Hepatotoxicity and tumorigenicity induced by metabolic activation of pyrrolizidine alkaloids in herbs. Current Drug Metabolism 2011;12:823‐34. - PubMed
Luqman 2006
    1. Luqman S, Rizvi SI. Protection of lipid peroxidation and carbonyl formation in proteins by capsaicin in human erythrocytes subjected to oxidative stress. Phytotherapy Research 2006;20:303‐6. - PubMed
Lyss 1997
    1. Lyss G, Schmidt TJ, Merfort I, Pahl HL. Helenalin, an anti‐inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF‐kappaB. Biological Chemistry 1997;378:951‐61. - PubMed
McGauran 2010
    1. McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, Kaiser T. Reporting bias in medical research ‐ a narrative review. Trials 2010;11:37. - PMC - PubMed
Melzig 2005
    1. Melzig MF, Henke K. Inhibition of thrombin activity by selected natural products in comparison to neutrophil elastase. Planta Medica 2005;71:787‐9. - PubMed
Moher 2001
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel‐group randomized trials. Annals of Internal Medicine 2001;134:657‐62. - PubMed
Moon 2010
    1. Moon DO, Kim MO, Lee JD, Choi YH, Kim GY. Rosmarinic acid sensitizes cell death through suppression of TNF‐alpha‐induced NF‐kappaB activation and ROS generation in human leukemia U937 cells. Cancer Letters 2010;288:183‐91. - PubMed
Nolano 1999
    1. Nolano M, Simone DA, Wendelschafer‐Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: Parallel loss of epidermal nerve fibers and pain sensation. Pain 1999;81:135‐45. - PubMed
Pham 2003
    1. Pham T, Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, et al. Outcome variables for osteoarthritis clinical trials: The OMERACT‐OARSI set of responder criteria. Journal of Rheumatology 2003;30:1645‐54. - PubMed
Pham 2004
    1. Pham T, Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT‐OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis and Cartilage 2004;12:389‐99. - PubMed
Sauer 2001
    1. Sauer SK, Reeh PW, Bove GM. Noxious heat‐induced CGRP release from rat sciatic nerve axons in vitro. European Journal of Neuroscience 2001;14:1203‐8. - PubMed
Schmitz 2010
    1. Schmitz N, Kraus VB, Aigner T. Targets to tackle‐‐the pathophysiology of the disease. Current Drug Targets 2010;11:521‐7. - PubMed
Schröder 1990
    1. Schröder H, Lösche W, Strobach H, Leven W, Willuhn G, Till U, Schrör K. Helenalin and 11 alpha,13‐dihydrohelenalin, two constituents from Arnica montana L., inhibit human platelet function via thiol‐dependent pathways. Thrombosis Research 1990;57:839‐45. - PubMed
Schunemann 2011a
    1. Schunemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, updated March 2011.
Schunemann 2011b
    1. Schunemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, updated March 2011.
Siedle 2002
    1. Siedle B, Cisielski S, Murillo R, Löser B, Castro V, Klaas CA, et al. Sesquiterpene lactones as inhibitors of human neutrophil elastase. Bioorganic & Medicinal Chemistry 2002;10:2855‐61. - PubMed
Siedle 2003
    1. Siedle B, Gustavsson L, Johansson S, Murillo R, Castro V, Bohlin L, Merfort I. The effect of sesquiterpene lactones on the release of human neutrophil elastase. Biochemical Pharmacology 2003;65:897‐903. - PubMed
Taniguchi 1994
    1. Taniguchi Y, Deguchi Y, Saita M, Noda K. Antinociceptive effects of counterirritants. Nihon Yakurigaku Zasshi 1994;104:433‐46. - PubMed
Tornhamre 2001
    1. Tornhamre S, Schmidt TJ, Näsman‐Glaser B, Ericsson I, Lindgren JA. Inhibitory effects of helenalin and related compounds on 5‐lipoxygenase and leukotriene C4 synthase in human blood cells. Biochemical Pharmacology 2001;62:903‐11. - PubMed
van den Berg 2011
    1. Berg WB. Osteoarthritis year 2010 in review: Pathomechanisms. Osteoarthritis and Cartilage 2011;19:338‐41. - PubMed
Verma 2010
    1. Verma N, Tripathi SK, Sahu D, Das HR, Das RH. Evaluation of inhibitory activities of plant extracts on production of LPS‐stimulated pro‐inflammatory mediators in J774 murine macrophages. Molecular and Cellular Biochemistry 2010;336:127‐35. - PubMed
Woerdenbag 1994
    1. Woerdenbag HJ, Merfort I, Passreiter CM, Schmidt TJ, Willuhn G, Uden W, et al. Cytotoxicity of flavonoids and sesquiterpene lactones from Arnica species against the GLC4 and the COLO 320 cell lines. Planta Medica 1994;60:434‐7. - PubMed
Yosipovitch 1996
    1. Yosipovitch G, Szolar C, Hui XY, Maibach H. Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin. Archives of Dermatological Research 1996;288:245‐8. - PubMed
Yudin 2012
    1. Yudin Y, Rohacs T. Regulation of TRPM8 channel activity. Molecular and Cellular Endocrinology 2012;353:68‐74. - PMC - PubMed
Zhang 2009
    1. Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, et al. EULAR evidence based recommendations for the diagnosis of hand osteoarthritis ‐ report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of Rheumatic Diseases 2009;68:8‐17. - PubMed
Zhang 2010
    1. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clinical Geriatric Medicine 2010;26:355‐69. - PMC - PubMed
Zhang 2010a
    1. Zhang W, Doherty M, Peat G, Bierma‐Zeinstra MA, Arden NK, Bresnihan B, et al. EULAR evidence‐based recommendations for the diagnosis of knee osteoarthritis. Annals of Rheumatic Diseases 2010;69(3):483‐9. - PubMed
Zhao 1992
    1. Zhao ZQ, Yang HQ, Zhang KM, Zhuang XX. Release and depletion of substance P by capsaicin in substantia gelatinosa studied with the antibody microprobe technique and immunohistochemistry. Neuropeptides 1992;23:161‐7. - PubMed

References to other published versions of this review

Cameron 2007
    1. Cameron M, Chrubasik S, Parsons T, Gagnier J, Blümle A, Little C. Herbal therapy for treating osteoarthritis: Update of a Cochrane review. Annals of the Rheumatic Diseases 2007;66 Suppl II:494.
Cameron 2009
    1. Cameron M, Gagnier J, Little C, Parsons T, Blümle A, Chrubasik S. Evidence of the effectiveness of herbal medicinal products in the treatment of arthritis. Part A: Osteoathritis. Phytotherapy Research 2009;23:1497‐1515. [DOI: 10.1002/ptr.3007] - DOI - PubMed
Little 2000
    1. Little CV, Parsons T, Logan S. Herbal therapy for treating osteoarthritis. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD002947] - DOI - PubMed

Publication types